Tag Archives: Biotech

The Little Orphan That Could: How Alexion is Going Global

Since the initial FDA approval of its flagship orphan drug Soliris in 2007, Alexion Pharmaceuticals has done well for itself as a small biotech firm that focuses on ultra-rare disease. So well in fact, that instead of partnering, the company has taken global expansion into its own hands. Apart from a pipeline that includes asfotase […]
Posted in Biotech, Global, Manufacturing, Market Access, Orphan Drugs, Strategy, Supply Chain | Also tagged , , , , , , , | Leave a comment

Europe's Bioscience 'Oscars': The Contenders

By Peter O’ Donnell. Europe’s closest thing to an Oscar’s ceremony for bioscience will take place in early October. The EuropaBio award for the most innovative European Union biotechnology firm is limited to firms with fewer than 250 staff or turnover or balance sheet of less than about $50 million. The aim is to encourage […]
Posted in Europe, Global, Guest Blog | Also tagged , , | Leave a comment

New York Pharma Forum: Together We Stand

Participants in the 23rd Annual NYPF General Assembly last Friday outlined the many challenges facing industry, and the importance of collaboration as a way to move forward.
Posted in Biotech, Events, leadership, People, R&D, Strategy, Technology | Also tagged , , , , , , , , , , | Leave a comment

CETP Inhibitors: Blockbusters that Never Ran?

The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, leadership, R&D, Technology | Also tagged , , , , , , | Leave a comment

Uncertain Outlook for Pharma and Biotech Deals Following 'Turbulent' 2011

Peter Young, President and Managing Director of international investment bank Young & Partners, looks at what lies ahead for pharma and biotech following a turbulent 2011. The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will […]
Posted in Global, Guest Blog, leadership, Strategy | Also tagged , , , , | Leave a comment
  • Categories

  • Meta